P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Articles > Article ยท 2019
Authors: S. Kilickap, U. Demirci, F. Bugdayci, D. Tural, T. Korkmaz, S. Paydas, C. Yilmaz, H. Turna, A. Sezer, H. Yesil Cinkir, K. Okutur, M. Erman, Y. Eralp, D. Cabuk, A. Isikdogan, A. Demirkazik, A. Karaoglu, D. Yazilitas, F. Cay Senler, P.F. Yumuk, H. Coskun, I. Yildiz, I. Oztop, I. Beypinar, K. Aydin, M. Kaplan, N. Meydan, O.F. Olmez, O. Ozyilkan, S. Seber, C. Arslan, M.A. Sendur, I. Cicin
Journal of Thoracic Oncology, International, WoS, 2019, vol 14, pp S558-S559